Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
Q&A: Anat Loewenstein recaps the 2025 EURETINA meeting | Ophthalmology Times
Photo of Anat Loewenstein at EURETINA 2025 The 25th EURETINA conference was a landmark event, attracting 11,000 participants from around the world. Anat Loewenstein, MD, the 2025 The president of EURETINA, highlighted the meeting’s comprehensive scientific program, featuring sessions on…
Justis P. Ehlers, MD, on the HELIOS trial for NPDR | Ophthalmology Times
Note: Captions are generated with the assistance of AI. Justis Ehlers, MD, spoke with Ophthalmology Times to share key findings from his recent presentation at the 2025 Retina Society meeting, which was held in Chicago, Illinois. Ehlers shared data from…
Care of newly diagnosed POAG impacted by patient wealth, area of residence | Ophthalmology Times
(Image credit: AdobeStock/masud) The results of a new cohort study found that newly diagnosed primary open-angle glaucoma (POAG) in patients who were in the lowest wealth quartile was “substantially” less likely to reach the recommended reduction and the patients “considerably”…
Optos and Toku to incorporate BioAge AI into existing retinal imaging devices | Ophthalmology Times
(Image credit: AdobeStock/hakule) Optos and Toku have reached an agreement to make Toku’s BioAge available to users of Optos Daytona, Monaco, MonacoPro, and California devices in the United States. The companies state that by incorporating the AI solution, BioAge, eye…
iVeena secures $2 million NEI SBIR grant to advance pediatric myopia therapy | Ophthalmology Times
iVeena Delivery Systems has been awarded a $2 million phase 2 Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) of the National Institutes of Health (NIH). The funding will help to advance development of novel topical eye…
Part 6: What if? Curing any eye disease with the snap of your finger | Ophthalmology Times
In celebration of Ophthalmology Times‘ 50th anniversary, we asked leading experts in the field, in a perfect world, if they had the ability to cure one eye disease or condition in the snap of their finger, what they would choose…
Virtual Vision Health and VirtuaLens enter partnership to accelerate virtual reality in eyecare | Ophthalmology Times
(Image credit: AdobeStock/matrosovv) Virtual Vision Health and VirtuaLens have entered a strategic partnership to expand access to and accelerate adoption of VR screening and patient education tools. The Virtual Eye VR platform from Virtual Vision Health offers an untethered, all-in-one…
Q&A: Stela Vujosevic shares why the staging system for diabetic eye conditions should be updated | Ophthalmology Times
Photo of Stela Vujosevic at the 2025 EURETINA meeting in Paris, France Stela Vujosevic, Md, PhD, FEBO, presented the need for a new staging system for diabetic retinopathy and diabetic macular edema at the 2025 EURETINA meeting in Paris, France.…
ExSight Ventures invests in RevOpsis Therapeutics to further AMD treatment candidate | Ophthalmology Times
Image credit: AdobeStock/jirsak ExSight Ventures invested in RevOpsis Therapeutics, a company developing a novel class of multispecific antibody-based treatments designed to address significant unmet needs in ophthalmology. The company states that initial focus will be on the developing treatment for…
Investigators share positive results of DAVIO 2 trial at EURETINA 2025 | Ophthalmology Times
(Image credit: AdobeStock/THANANIT) EYP-1901, known as the vorolanib intravitreal insert, was highlighted at the EURETINA 2025 meeting, which was held in Paris, France. In 2 presentations, researchers shared the recent results from the DAVIO 2 clinical trial. What is EYP-1901?…